UK Markets open in 4 hrs 50 mins

Aileron Therapeutics, Inc. (ALRN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4120-0.0082 (-1.95%)
At close: 04:00PM EDT
0.3950 -0.02 (-4.13%)
After hours: 04:05PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.57
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 31.3400
52-week low 30.3200
50-day moving average 30.4345
200-day moving average 30.6041

Share statistics

Avg vol (3-month) 3286.8k
Avg vol (10-day) 3230.39k
Shares outstanding 590.57M
Implied shares outstanding 6N/A
Float 858.34M
% held by insiders 19.02%
% held by institutions 135.60%
Shares short (28 Apr 2022) 4153.59k
Short ratio (28 Apr 2022) 40.39
Short % of float (28 Apr 2022) 40.22%
Short % of shares outstanding (28 Apr 2022) 40.17%
Shares short (prior month 30 Mar 2022) 4145.17k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Dec 2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-51.30%
Return on equity (ttm)-93.33%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)-17.01M
EBITDA -26.48M
Net income avi to common (ttm)-26.16M
Diluted EPS (ttm)-0.3190
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)45.93M
Total cash per share (mrq)0.51
Total debt (mrq)162k
Total debt/equity (mrq)0.37
Current ratio (mrq)10.69
Book value per share (mrq)0.55

Cash flow statement

Operating cash flow (ttm)-23.75M
Levered free cash flow (ttm)-13.5M